ProKidney (NASDAQ:PROK – Get Free Report) and Pyxis Oncology (NASDAQ:PYXS – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.
Risk & Volatility
ProKidney has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.
Valuation & Earnings
This table compares ProKidney and Pyxis Oncology”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ProKidney | $818,000.00 | 704.07 | -$68.99 million | ($0.55) | -3.46 |
| Pyxis Oncology | $11.04 million | 25.29 | -$79.62 million | ($1.41) | -2.37 |
ProKidney has higher earnings, but lower revenue than Pyxis Oncology. ProKidney is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and target prices for ProKidney and Pyxis Oncology, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProKidney | 1 | 0 | 1 | 1 | 2.67 |
| Pyxis Oncology | 1 | 1 | 8 | 0 | 2.70 |
ProKidney currently has a consensus target price of $12.00, indicating a potential upside of 529.92%. Pyxis Oncology has a consensus target price of $8.75, indicating a potential upside of 161.43%. Given ProKidney’s higher possible upside, analysts plainly believe ProKidney is more favorable than Pyxis Oncology.
Institutional & Insider Ownership
51.6% of ProKidney shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 39.8% of ProKidney shares are held by company insiders. Comparatively, 5.7% of Pyxis Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares ProKidney and Pyxis Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProKidney | -10,288.39% | N/A | -27.39% |
| Pyxis Oncology | N/A | -215.23% | -112.19% |
Summary
ProKidney beats Pyxis Oncology on 10 of the 15 factors compared between the two stocks.
About ProKidney
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
About Pyxis Oncology
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.
